Xingjuan Chao Sells 79,000 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 79,000 shares of the firm’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $21.27, for a total transaction of $1,680,330.00. Following the completion of the transaction, the chief executive officer directly owned 741,248 shares in the company, valued at approximately $15,766,344.96. The trade was a 9.63% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Xingjuan Chao also recently made the following trade(s):

• On Thursday, December 4th, Xingjuan Chao sold 25,000 shares of CeriBell stock. The stock was sold at an average price of $18.82, for a total value of $470,500.00.
• On Monday, December 1st, Xingjuan Chao sold 25,000 shares of CeriBell stock. The stock was sold at an average price of $16.59, for a total value of $414,750.00.
• On Friday, November 21st, Xingjuan Chao sold 50,000 shares of CeriBell stock. The shares were sold at an average price of $15.13, for a total value of $756,500.00.

CeriBell Trading Up 1.1%

Shares of CeriBell stock opened at $23.07 on Friday. The company has a market capitalization of $855.90 million, a P/E ratio of -15.28 and a beta of 1.02. The stock has a fifty day simple moving average of $17.78 and a 200 day simple moving average of $15.08. CeriBell, Inc. has a 12-month low of $10.01 and a 12-month high of $26.04. The company has a current ratio of 12.65, a quick ratio of 12.25 and a debt-to-equity ratio of 0.12.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.06. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%.The business had revenue of $22.59 million for the quarter, compared to analysts’ expectations of $21.78 million. On average, sell-side analysts anticipate that CeriBell, Inc. will post -2.46 earnings per share for the current fiscal year.

Institutional Trading of CeriBell

Large investors have recently bought and sold shares of the company. Geode Capital Management LLC increased its stake in shares of CeriBell by 55.4% in the second quarter. Geode Capital Management LLC now owns 447,936 shares of the company’s stock worth $8,391,000 after purchasing an additional 159,698 shares in the last quarter. Squarepoint Ops LLC bought a new position in CeriBell in the 2nd quarter worth approximately $1,054,000. Police & Firemen s Retirement System of New Jersey grew its stake in CeriBell by 161.0% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock valued at $106,000 after buying an additional 3,502 shares in the last quarter. F m Investments LLC bought a new stake in CeriBell during the 2nd quarter valued at $381,000. Finally, Peregrine Capital Management LLC purchased a new stake in shares of CeriBell during the second quarter worth $6,399,000.

Wall Street Analysts Forecast Growth

Several research firms have commented on CBLL. Canaccord Genuity Group increased their price objective on shares of CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. BTIG Research reaffirmed a “buy” rating and set a $30.00 price target on shares of CeriBell in a research report on Monday, December 15th. TD Cowen cut their price objective on CeriBell from $36.00 to $20.00 and set a “buy” rating on the stock in a research report on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CeriBell in a research report on Wednesday, October 8th. Finally, Cowen reissued a “buy” rating on shares of CeriBell in a report on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, CeriBell has a consensus rating of “Moderate Buy” and a consensus price target of $24.67.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.